8th European Conference on Rare Diseases & Orphan Products (ECRD 2016) by Schlander, Michael et al.
Orphanet Journal of Rare Diseases 2016, 11(Suppl 1):143
DOI 10.1186/s13023-016-0515-yMEETING ABSTRACTS Open Access8th European Conference on Rare
Diseases & Orphan Products (ECRD 2016)
Edinburgh, UK. 26-28 May 2016
Published: 1 November 2016O1
The European Social Preferences Measurement (ESPM) study
project: social cost value analysis, budget impact, commercial
life cycle revenue management, and the economics of
biopharmaceutical Research & Development (R&D)
Michael Schlander1,2,3, Søren Holm4, Erik Nord5, Jeff Richardson6, Silvio
Garattini7, Peter Kolominsky-Rabas8, Deborah Marshall9, Ulf Persson10,
Maarten Postma11, Steven Simoens12, Oriol de Solà Morales13,
Keith Tolley14, Mondher Toumi15, Harry Telser16
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), An der
Ringkirche 4, D-65197 Wiesbaden, Germany; 2Mannheim Medical Faculty,
Institute of Public Health, University of Heidelberg, Ludolf-Krehl-Strasse
7-11, D-68167 Mannheim, Germany; 3University of Applied Economic
Sciences, Ernst-Boehe-Strasse 4, D-67059 Ludwigshafen, Germany;
4Centre for Social Ethics and Policy, University of Manchester, Oxford
Road, Manchester M13 9PL, UK; 5School of Pharmacy; University of Oslo,
Sem Sælands vei 3 Farmasibygningen, N-0371 Oslo, Norway; 6Centre for
Health Economics, Monash University; Clayton, Victoria 3800; Australia;
7IRCCS – Istituto di Richerche Farmacologiche Mario Negri, Via Giuseppe
La Masa 19, I-20156 Milan, Italy; 8Interdisziplinäres Zentrum für Public
Health (IZPH); Universitätsklinikum Erlangen, Schwabachanlage 6, D-
91054 Erlangen, Germany; 9Health Research Innovation Centre,
Cumming School of Medicine, University of Calgary, 2500 University
Dr. NW, Calgary, Alberta, T2N 1N4, Canada; 10The Swedish Institute for
Health Economics (IHE), Box 2127, S-220 02 Lund, Sweden; 11Department
of Pharmacy, University of Groningen, Antonius Deusinglaan 1 9713 AV
Groningen, The Netherlands, and Department of Epidemiology, University
Medical Center Groningen, University of Groningen, Hanzeplein 1 9713 GZ
Groningen, The Netherlands; 12KU Leuven Department of Pharmaceutical
and Pharmacological Sciences, Herestraat 49, B-3000 Leuven, Belgium;
13Institut Investigació Sanitaria Pere Virgili (IISPV), Avenir 1 Ppal 1ª; E-08006
Barcelona; 14Tolley Health Economics Ltd, 19 Bath Road, Buxton, Derbyshire
SK17 6HH, Great Britain; 15UFR d'Odontologie, University Claude Bernard
Lyon I; 11 rue Guillaume Paradin; F-69372 Lyon Cedex 08, France;
16Polynomics AG, Baslerstrasse 44, CH-4600 Olten, Switzerland
Correspondence: Michael Schlander (Michael.Schlander@innoval-hc.com;
michael.schlander@medma.uni-heidelberg.de; michael.schlander@hs-lu.de) –
University of Applied Economic Sciences, Ernst-Boehe-Strasse 4, D-67059
Ludwigshafen, Germany
Orphanet Journal of Rare Diseases 2016, 11(Suppl 1):O1
The cost of new medicines has never been as controversial as now-
adays. Health care policy makers are concerned that rising drug
prices may lead to unsustainable growth of health care expenditures.
The debate, however, frequently suffers from confusion of cost per
unit and budget impact, i.e., the notion of “affordability.”
In their quest for value for money, policy makers have turned to
systematic health technology assessments (HTAs) as a tool to aid the
appraisal of the clinical, economic, social, legal and ethical impli-
cations of the adoption, and the appropriate use, of medical
technologies.
HTAs of interventions for rare and ultra-rare disorders (URDs) present
specific challenges. Some treatments for URDs are associated with
acquisition costs exceeding 100,000€ per patient year, consequently© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zenot meeting conventional benchmarks for cost effectiveness (CE). On
the other hand, the budgetary impact of orphan medicinal products
(OMPs) has been limited and seems unlikely to escalate massively in
the near future.
Payers have often been more concerned about the cost of adding
new programs than about their CE, and many HTA agencies have
created exemptions for OMPs or URDs. This corresponds to the strat-
egy of manufacturers to maximize life cycle revenues, in light of the
high fixed / low variable cost structure of the R&D-based biopharma-
ceutical industry. Recent estimates of the average R&D cost per new
product converge in a range between US- 1.0 and 1.9 billion, when
factoring in out-of-pocket costs, risk of failure, development times,
and cost of capital. The economics of R&D may, at least in part, ex-
plain the observed inverse relationship between acquisition costs per
patient and prevalence.
Exempting OMPs from CE benchmarks may have been a pragmatic
work-around, but created controversy about the justification of a
special status for OMPs (or URDs). The situation would be different if
the focus of health economic analyses was shifted towards the social
value associated with patient access to interventions. Then, oppor-
tunity cost would be represented by budgetary impact (or cumula-
tive transfer cost).
Since societal value is not fully captured by simple aggregation of in-
cremental health gains (weighted based on individual preferences),
social norms and preferences need to be taken into account, too.
Despite the increasing number of studies showing the relevance of
social preferences, empirical evidence has been limited regarding
their relative importance, including their interaction, and the impact
of framing effects. The ESPM project has been designed to further
our understanding of relevant social preferences.
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The potential offered by newborn screening to improve the lives
of patients by enabling early and effective treatment is well
established. Each year almost 1,000 children in the USA and Eur-
ope are identified with phenylketonuria alone as part of national
programs and this has operated for approximately 50 years in
many well developed countries with very significant and cost ef-
fective health benefits.
More recently the potential to expand these programs to include
many more metabolic conditions utilizing tandem mass spectrometry
has been adopted by many European states and notably within the
USA who have taken a lead in these developments, currently screen-
ing for more than 50 disorders in all babies.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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proaches 100 %, the positive predictive value, particularly for some
disorders, is less complete and may lead to uncertainty for some
families. In addition, the spectrum of disease severity has widened to
include mild variants with unclear significance. This requires careful
management. The potential offered by next generation sequencing
performed on the original dried blood spot samples as an adjunct to
biochemical testing may provide useful additional information to
guide treatment or even provide the means to consider new disor-
ders but it also raises a number of key questions: how do we select
the conditions to test and who should choose, how do we provide
useful and understandable pre-screening information to parents and
gain meaningful consent, what do we do with genetic information
such as carrier status or the identification of variants that may not
have significance in childhood?
Public and patient consultation is key but may require greater soci-
etal awareness to be meaningful. The opportunities afforded by im-
proved information, given in an accessible form, during pregnancy
may help inform and stimulate this debate. In relation to whole
population screening programmes it is increasingly the responsibility
of health service planners, not only to evaluate new technological so-
lutions and judge their clinical effectiveness, but also to actively seek
means of public engagement to educate, inform and involve poten-
tial health users and the public in the dialogue.
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To measure the benefits or harms to a patient who receives an inter-
vention is a key feature to improve quality of care. This usually in-
volves a strategy to define and prioritize areas for improvement; to
apply appropriate (i.e. reproducible, statistically significant and GCP-
compliant) measures to assess these areas; to determine a baseline
reference of current practices using the selected measures and to re-
assess and monitor the effect of interventional improvement efforts.
This process may guide and focus accountability and quality im-
provement programs.
In rare diseases (RD) with no existing cure, an only small number of
affected individuals along with limited registry and generalizable re-
search data as well as inter- and intraindividually highly variable
course (subtypes) and occasionally early mortality, the establishment
of comprehensive, reliable, validated and feasible outcome measures
is particularly challenging. All this prototypically applies for Epider-
molysis bullosa (EB), a group of rare, heterogenous and complex her-
itable blistering diseases. In order to improve the interpretation and
quantification of results of (partly highly promising) interventions in
EB, clinical, laboratory, microscopic and ultrastructural as well as mo-
lecular outcome measures have been proposed that should assist in
appropriately reflecting the disease activity and burden and captur-
ing both, clinician assessment as well as patient/parent perceptions:
iscorEB [1], BEBS [2], EBDASI [3]. A distinct example of outcome mea-
sures in untreatable EB is reflected by clinical follow up and watchful
waiting in patients with EB nevi. These moles, although clinically and
dermatoscopically frighteningly resembling melanomas, usually ex-
hibit a benign course according to our experience of more than
25 years. Finally, at the edge of a new era of curative treatment ap-
proaches, ex vivo gene therapy trials have revealed highly specific
and measurable determinants of interventional success [4,5].
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Several models of Integrated Service Delivery networks were experi-
mented and tested, but most of them are designed according to a full
integration model. PRISMA is the only example of a coordinated-type
model to be developed and fully implemented with a process and out-
come evaluation. The PRISMA model includes the following compo-
nents to enhance the integration: 1) formal mechanism to manage co-
operation between decision-makers and managers of all services and
organizations, 2) the use of a single entry point, 3) a case management
process, 4) Individualized Service Plans, 5) a unique assessment tool
with a case-mix system, and 6) a computerized system for communicat-
ing between institutions and professionals.
The PRISMA model was experimentally implemented in three areas
(urban, rural with or without a local hospital) in Quebec, Canada and
research was carried out using both qualitative and quantitative data
to evaluate its process and impact. The impact study was
population-based with a quasi-experimental design on 1500 subjects
over 75 years old followed up for four years. Significant impact of
the prevalence and incidence of functional decline, satisfaction with
services and empowerment was observed. There was a reduction in
the number of Emergency Room visits and hospitalisations. The over-
all cost was not higher in the experimental group, even when imple-
mentation cost was included.
The PRISMA model was then implemented all over the province of
Quebec from 2005 to 2015. The 70 % implementation rate threshold
was reached in 2014 in all regions. Budget constraints and concomi-
tant reforms (merging of institutions) slowed down the implementa-
tion. Many lessons were learned from this implementation: the case
managers should be formally trained and accredited, structural inte-
gration by merging is not necessarily fostering functional integration,
information technology development is a critical factor for integra-
tion, and appropriate funding scheme should be considered as an
enabling factor for integration.
The PRISMA model has already demonstrated its efficiency and feasi-
bility for frail older persons. It could be adapted for rare disease to
improve continuity of care and integration of services.
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Background
Patient- and caregiver-generated information online arises from a
patient population that is more knowledgeable about its own
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bile apps can provide information to safety intelligence in areas
where other sources fall short.
Methods
Challenges associated with mining unstructured data, including filter-
ing noise and translating patient vernacular to medical terms, can be
addressed through automated methodologies [1,2]. In this abstract
we discuss ways in which social media listening can be beneficial for
rare disease patients.
Results
Rare disease patients post publicly about side effects they are experi-
encing. For example, one patient mentioned a warning sign for ser-
ious complications: “Had constant ringing in my ears since last week.
Can't work out whether it's my sinuses, or if it's [orphan-designated]
tobramycin related. My levels were fine.” First, data from patient- and
caregiver-generated social media can be a tool for advocacy. Online
patient communities can collectively change the discussion on what
matters for rare diseases. Systematically mining public conversations
can amplify anecdotes into powerful and accurate representations of
the patient journey. Second, travel to medical appointments, even
short distances, can be a difficulty for rare disease patients. Using on-
line electronic diaries and data mining, we can allow patients to rec-
ord experiences in their own words, and send processed reports to
physicians. Third, social media can allow rare disease communities to
define what matters to them as outcomes for new therapies. Increas-
ing lifespan critical, but may not be the only thing that matters to
patients. Improving quality of life is often relegated to “secondary
endpoints.” Social listening can help reveal and prioritize other out-
comes that are important. Fourth, combining genetic or clinical data
with social media may identify clinical trial eligibility more quickly.
Conclusions
While safety data generated from digital tools may not consist of the
same elements as a traditional safety report, they nonetheless may
contain valuable information that to contextualize how medical prod-
ucts are being used. As such, digital health information is unlikely to
replace spontaneous, observational and clinical data, but may serve
to augment traditional data sources. Privacy concerns for patients
with rare disease may be heightened relative to more prevalent con-
ditions. Efforts to obtain explicit permission should be made, directly
from patients when feasible, and at least from forum administrators
and the community more broadly. Ultimately, the processed data
should be provided back to patients to empower advocacy.
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Rationale and project objective
Via Opta Apps is a suite of 4 applications, Via Opta Daily, Via Opta
Navigator, Via Opta Simulator and Via Opta Eye Life that have been
specifically designed for people living with low vision to improve
their quality of life.
Background
Novartis is committed to patients and patient engagement is crucial
to help the company develop services and solutions that will im-
prove the lives of people living with low vision and their families.The co-creation of this digital tool was identified as one critical suc-
cess factor. Therefore, Novartis has developed this project in partner-
ship with patient organisations in order to address the specific needs
of patients.
Project description and results
The project was co-created over 2 years with input from patient organi-
sations: 2 patient forums in collaboration with Retina International, an
umbrella patient organization of 20 members representing 11
European Countries and others like ECOO, EMHF, AMDAI.
■ Via Opta Daily available in 12 languages is designed as a personal
assistant to help people with low vision in their activities of daily liv-
ing like colour, objects, scenes and money recognition.
■ Via Opta Navigator offers an experience that can be life changing
for people living with low vision by helping them to increase their
mobility and regain independence as it offers turn by turn complete
navigation that was built specifically for visually impaired users.
■ Via Opta Simulator has been designed for patients, their families,
healthcare professionals and caregivers as an app to provide a lens
at what it is like to live with visual impairment.
■ Via Opta Eye Life which provides a real life virtual reality experience
demonstrating the world from a visually impaired user perspective.
The apps can be downloaded for free from Apple iOS and Android
(Google Play) stores on your mobile devices and Novartis is dedi-
cated towards improving and updating them to continue to add
value in the daily life of patients.
Partners
Novartis is a partner of EURORDIS and of several Patient Organisations
established at Regional and Country level in Europe.
Outcomes
■ Interaction with Patient organisations in Advisory Boards and
Forums to share and co-create future digital tools.
■ Develop solutions that will improve the lives of people living with
low vision and their families.
■ Raise awareness of the disease condition thanks to an international
network and alliances.O7
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The challenges in researching therapies in rare diseases are well
recognized – amongst them are the exceptionally low disease preva-
lence, challenges in identifying or finding patients (let alone adequate
numbers of patients), small and particularly often very heterogeneous
patient populations, and limited knowledge of natural history (so we
often don’t know “what would have happened if…”).
The IRDiRC Therapy Scientific Committee recommends: Encouraging,
supporting and establishing early and continuous dialogue on clinical
development strategies and wide evidence generation (e.g. natural his-
tory, registry, clinical trial design, clinical endpoints, surrogate end-
points, patient centred outcomes, regulatory strategy, medical practice,
public health strategy) with all relevant stakeholders such as patient
representatives, medical experts, researchers, scientific societies, regula-
tors, health technology assessors, payers and sponsors when appropri-
ate. This could be done through dedicated workshops, safe harbours
where knowledge could be shared in a non-competitive manner.
Furthermore, it recommends: Encouraging, supporting and develop-
ing small population clinical trials (e.g. exploring the application of
innovative methods). This is an essential step to gather more relevant
data at the time of benefit-risk assessment.
To contribute solutions to these recommendations, the IRDiRC Execu-
tive Committee set up a Task Force that brought together 35 experts
from Europe, the United States and Japan; it met in London on 3rd
May 2016. While the Task Force had a strong base of statistical ex-
pertise, other contributions including patients, physicians, regulators,
industry members, scientists and academics all contributed substan-
tially to the recommendations of the group.
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under six headings: different study methods/designs vs. types of con-
ditions; adequate safety data; multi-arm or “platform trial” designs;
decision-analytic approaches and rational approaches to adjusting re-
quired levels of evidence; extrapolation problems and opportunities;
and patients’ engagement in study design.
A report of the Task Force (including a summary of the workshop) is
currently in preparation and will be published on the IRDiRC website.
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Background
HAE International (HAEi) and the HAE Association (HAEA), which rep-
resent hereditary angioedema (HAE) patient groups around the
world, in partnership with Shire, developed the HAE patient identifi-
cation and diagnosis program in response to speed timely and accur-
ate diagnosis. Patients often deal with lengthy delays because of
limited awareness and inadequate information. Health care profes-
sionals are also often unaware of the disease and its presentation.
Materials and methods
This program addressed these problems by identifying gaps in phys-
ician, patient and family member knowledge and developing a core
set of materials to educate them. As an autosomal dominant disease,
family testing was identified by patient groups and the company as
having the greatest impact on more timely and accurate diagnosis.
General materials were created for all three key stakeholders, provid-
ing information on the disease, diagnosis, and confirmatory testing.
Additional resources on family testing were created to aid physicians
in their discussion with patients, as well as for patients in their dis-
cussion with their families. Materials were developed by patients for
patients, showing a sensitive approach to their content.
Next, member organisations of HAEi and HAEA were engaged to
understand how to use these new materials in their countries. Forty-one
member groups worldwide were trained by these larger organisations.
HAEi, HAEA and Shire organised webinars regional workshops to facili-
tate education in countries where there were no patient organisations.
Results
This program has resulted in increased awareness of HAE and im-
proved diagnostic training for healthcare professionals internation-
ally. The campaign reached over 340 patients in the United States
alone with diagnosis/treatment information. There was very positive
feedback from the HAE community with an increase in the number
of patients and members of country organisations, including over
700 new members in the United States. Working together, HAEi,
HAEA, and Shire have broadened awareness of the disease and in-
creased time to diagnosis.
Conclusions
By working together strategically, all parties were each able to bring
individual strengths and knowledge to the project for the benefit of
patients. The result was not just more information but also a frame-
work for global and regional organisations to ensure that member
groups are able to execute effectively. This cooperation between in-
dustry and advocates provides an approach that can be replicated
across other disease areas.
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Elocta, Sobi wanted to explore whether more user-friendly packaging
and administration could make life easier for people with haemo-
philia. Haemophilia is a life-long, chronic condition that – untreated
or undertreated – causes bleeding, including into joints, resulting in
progressive joint damage.
Sobi had heard that packaging and dosing syringes are not al-
ways designed to meet the needs of people with haemophilia,
being sometimes bulky and with syringes that are difficult to
manage. This could impact drug administration and treatment
compliance, particularly in children learning to self-inject, as well
as adults with impaired joint mobility, which can be a conse-
quence of haemophilia.
Working with organisations representing people with haemophilia,
Sobi initiated a dialogue with more than 100 individuals, including
carers and healthcare professionals. We asked people with haemo-
philia to record video diaries of their experience of treatment; and
travelled to meet with them for open conversations about the topics
that they had raised.
The insights allowed us to create a briefing document, which we
gave to an award-winning design company. The resulting series of
potential new designs for the packaging and syringes were shared
with the haemophilia community to explore if these designs would
better meet the needs of people with haemophilia.
In a process of ongoing dialogue and constant refinement, we
learned that size was the most important element. The resulting
packaging is more compact than most conventional therapies, which
simplifies storage and travel. It is also recyclable.
We also learned that it is important to facilitate injections, be-
cause people might have impaired grip function due to joint
damage; and for younger patients with small hands. With the
help of the community, we developed an innovative syringe
plunger rod with horizontal ribs and an extra centre grip with a
soft top, which increases friction and gives equal grip, even if it
is not pushed exactly squarely.
The packaging is also complete: everything needed to prepare and
inject the treatment is provided, i.e., drug, pre-filled solvent syringe,
low-resistance infusion set, sterile swabs, adhesive bandage and a
packaging leaflet.
Through genuine co-creation with people with haemophilia and the
community, we believe that Sobi has gathered new insights into
how packaging can be developed. We were able to build a genuine
dialogue with people with haemophilia, their carers and healthcare
professionals, which has created opportunities for continued valid-
ation and refinement of future approaches.
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Background
This event developed the aim: to encourage young adult Gaucher
patients to come together to exchange information and ideas; to
help improve the quality of life of the participants; to broaden their
horizons; to encourage them to take an active role in their national
associations and at a European/international level; to support the
work of finding and strengthening the future leaders of the EGA and
its member associations.
Content
The EGA wanted this to be a project that involved all member
associations, so once the project plan was created, members
were then asked to identify one participant from their own asso-
ciation. The first meeting took place in Frankfurt, November 2012
and was attended by 31 young Gaucher patients, ranging in age
Orphanet Journal of Rare Diseases 2016, 11(Suppl 1):143 Page 5 of 9from 17 to 34 years, representing twenty of our member coun-
tries, mainly from Europe. The main topics: 1/Getting to know
each other: This was the first time that most of the group had
met and so a lot of time was spent at the beginning of the
meeting to create a safe environment where everyone could
speak freely. 2/ Learning about Gaucher disease in order to edu-
cate the young patients in relation to the management of their
condition. 3/Workshops on special subjects that they wanted to
discuss. 4/Information about the EGA and the national associa-
tions. A second meeting took place in November 2015. There
were both new participants and some from the first meeting. The
program this time was similar to the first one but also included
training sessions on fundraising, social media and public relations.
Results
Both participants and member associations highlight that meeting
peers, sharing feelings and problems is the most important outcome.
Some participants wanted to be more active, but due to current per-
sonal situation, i.e. studies, this was not the time. Still many of these
young patients have become more involved in the work of their na-
tional groups, in EGA activities and even involved in EURORDIS activ-
ities. The group has continued to stay in touch using a closed
Facebook group. Feedback from the weekend has been used to
shape some of the EGA’s work programme: International Gaucher
Day, training and raising awareness for doctors, sharing best
practices in daily life and developing websites for all national
associations.
Conclusions
The project Go with Gaucher have reached its goals and have be-
come an ongoing project within the EGA working programme.P1
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Acanthamoeba Keratitis (AK) is a rare infectious eye disease
prevalent in contact lens wearers (over 85 % of AK cases) result-
ing from exposure to Acanthamoeba spp., ubiquitous free living
microorganisms. Symptoms can include severe eye pain, light
sensitivity, vision loss and in extreme cases corneal transplant
and enucleation (eye removal). There is currently no licensed
drug to treat AK.
The ODAK consortium of industry and academia are undertaking the
clinical development of PHMB (Polihexanide). The aim is to apply for
marketing authorisations to provide the first approved ophthalmic
intervention for the safe and effective treatment of this rare disease.
The ODAK consortium have already completed a retrospective study
which has shown efficacy of PHMB 0.02 % alone or in combination
with other anti-amoebic drugs [1]. A range of non-clinical studies
(including pharmacodynamics, pharmacokinetics and toxicology) on
novel formulations of PHMB have been carried out and resulting
in vitro and in vivo efficacy tests showed 0.02 % PHMB as the least ef-
fective formulation against Acanthamoeba polyphaga, with respect to
other tested PHMB concentrations (0.04 %, 0.06 %, 0.08 %) [3]. The
safety ocular profiles of three PHMB formulations (0.08 %, 0.25 % and
0.8 %) were assessed in an animal model indicating no relevant
treatment-related effects of PHMB ophthalmic solutions at 0.08 %
and 0.25 %. Only 0.8 % PHMB eye drops showed moderate/severe
ocular toxicity [2]. The toxicological data supported the plan to inves-
tigate PHMB 0.04 %, 0.06 %, 0.08 % (and placebo) eye drops in a
Phase I clinical trial. The trial held at three clinical centres in the
Netherlands and Belgium in 90 healthy volunteers was successfullycompleted in Q1 2016. A Phase III clinical trial is scheduled to begin
Q4 2016.
The ODAK project has faced particular challenges in establishing
patient involvement in the drug development pathway due to
the nature of the disease. Infection is unpredictable, disease out-
comes vastly differ patient to patient and engaging patients
once disease progression is resolved is difficult. There is no
established patient group for AK or patient registry. Patient cen-
tric information is lacking and patients can feel isolated, without
a forum to translate their experience. ODAK is working with pa-
tients to address these issues, identifying and engaging with pa-
tients for protocol and patient information leaflet design,
developing information on preventative care and support mate-
rials for the newly diagnosed, and using the Project website as
a go to site for patient stories and advice. The research leading
to these results has received funding through the European
Community's Seventh Framework Programme under grant agreement
No. 305661-2.
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Because of the complexity and rareness, people living with rare
diseases (PLWRD) are particularly vulnerable in the social- and
healthcare systems because standard procedures do not function
for these patients. Increased standardization in relation to social
support and healthcare procedures jeopardizes the possibility to
get the tailored treatment that PLWRD are dependent on, to live
good lives.
Rare Diseases Denmark’s Patient Navigators offers structured sup-
port to fill in the gaps and prevent PLWRD from falling into
cracks. The goal is to equalize disparities and promote health
and health literacy in the most vulnerable PLWRDs in Denmark.
Based on experience-based knowledge, Navigators provide per-
sonal guidance to vulnerable PLWRD to navigate the Danish
health care system and to access the social system. The volunteer
Navigator either suffers from a rare disease themselves or are a
relative to a PLWRD.
Navigators support and empower the wishes, priorities and deci-
sions of vulnerable PLWRD through the principle of helping them
to help themselves. In addition to the personal knowledge of the
Navigators, Rare Diseases Denmark provides an education and
continuously support program for the Navigators. Navigators sup-
port PLWRD for maximum 12 months - the navigation depends
Orphanet Journal of Rare Diseases 2016, 11(Suppl 1):143 Page 6 of 9entirely on the individual’s needs and the complexity of the
situation.
Providing coordination between and within the systems is a task for
the social- and health care professionals. With this project profes-
sionals and volunteers combine forces in co-creation contributing to
improve the conditions for PLWRD. Through co-creation partners
exchange ideas, resources and skills and create new learning
environments.
To study the impact of receiving support from a Navigator, all
PLWRDs involved in the project, answer the WHO-Five Well-being
Index questionnaire in the beginning and in the end of navigation.
The results gives an indication of the effect.
Originally the Patient Navigation concept was developed in the
US to eliminate barriers to timely diagnosis and treatment of can-
cer and other chronic diseases. The nation’s first Patient Navigation
program was conceived and initiated in 1990 in Harlem, New York,
by Dr. Harold Freeman [http://patientnavigatortraining.org/website/
documents/prework_%20freeman_principles_of_pn.pdf] Rare Diseases
Denmark has adjusted the model and made it suitable for PLWRD.
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Technology has been at the forefront of healthcare and with the
increase in dependence on smartphones The CATS Foundation
wanted to take advantage of the potential of this media by de-
veloping an app using video media that could provide support
and information to carers of children affected by Tay-Sachs or
Sandhoff.
The charity won the prestigious Patient Advocacy Leadership
Award that is run by Genzyme Corporation to create the app. In-
terviews with families affected by the diseases on subjects ran-
ging from symptom management to advice on care were
recorded to provide the ultimate in peer-to-peer support. The
app was launched to coincide with the International Rare Disease
day in 2015 where it was featured in the national press and pub-
licised through social media.
With an objective of educating carers and parents the app was given
the title of the “eAcademy for Tay-Sachs and Sandhoff Disease”. The
app was launched across simultaneous mobile phone and tablet op-
erating systems (Android, IOS and Windows) which meant that
people would be able to access and download it to their devices.
The majority of downloads have been from people in European
countries (47 %) and those in the US (39 %). As the app was devel-
oped by a UK based charity and is in English, it is no surprise that
the majority of downloads are from people in English speaking coun-
tries (71 %).
The development and launch of The eAcademy for Tay-Sachs and
Sandhoff Disease app has shown that parents and carers place a
high value on our peer-to-peer support model. Users of the app have
been able to gain advice on various care related subjects that can
have a dramatic affect on their ability to provide high quality care to
their children.
As a rare disease, which is notoriously difficult to diagnose, and
which has a prevalence rate of only 1 in 320,000 births it was never
expected that the app would have a huge download rate. However,
the volume of downloads exceeds the total members of The CATS
Foundation and has led to families in other countries reaching out to
the charity for support and information.We believe that the app should form a framework for other disease
specific organisations. Hearing directly from families about how they
manage symptoms and other aspects of care can have a positive im-
pact on users and can lead to them providing a higher level of care
for their child.
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Background
Neuronal Ceroid Lipofuscinoses (NCLs), commonly known as Batten
disease, are the most common of the rare neurodegenerative disor-
ders of children, affecting approximately 150-200 in the UK. There
are currently no cures for this group of devastating genetic diseases.
Symptoms include progressive dementia, motor decline, visual fail-
ure, and complex epilepsy leading to death at an early age.
BDFA Research Strategy
Research funding for rare diseases is fragmented and inadequate.
Patient organisations play a vital role in driving the research
agenda; to understand the disease mechanisms and bridge the
gap from bench to beside. The BDFA has developed a focused
and innovative research strategy meeting the complex demands
of all 14 types of the NCLs. Key strategic aims and collaborations
have been identified to promote excellence in the field of NCL
research.
The development of a screening method, using zebrafish, in CLN2
disease, by Dr. Claire Russell at the Royal Veterinary College, London
has identified a potential lead compound. Key to this project, was
the inclusion of direct family involvement and continuity of project
funding to ensure progress. Employing a robust, but flexible funding
model allowed for the identification of a potential repurpose use for
a compound in CLN2 disease and the establishment of an important
research resource for future studies.
The long term funding of a PhD studentship (Sophia Kleine Holthaus)
Institute of Ophthalmology (UCL) completed the challenging first
steps in finding a gene therapy treatment for visual failure in Batten
disease.
Conclusions
The current BDFA research strategy produces excellent results.
This innovative approach makes considerable and quicker pro-
gress towards identifying potential therapies. The key role of a
patient organisation in supporting investigators and driving re-
search should not be underestimated and the one key area to
address is facilitating dialogue with key stakeholders at an even
earlier stage, most notably raising the profile of the research with
potential commercial partners and the regulatory authorities. For
rare diseases, driving a research agenda makes a faster route to
successful therapies more likely. Innovation is key to where re-
sources are limited.
Carefully placed funding can produce high quality work enabling re-
searchers to apply for significant research awards from major grant
funding bodies. Projects funded by the BDFA were integral to suc-
cessful award to the BATCure consortium of a 3-year Horizon2020 re-
search grant.
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Background
Patients with rare diseases often have to endure a late diagnosis, a
lack of knowledge among specialists and healthcare workers, a lack
of effective treatments, and insufficient attention to scientific re-
search. To provide proper care, it is important to cluster expertise for
these diseases. This insight has led to the formation of centres of ex-
pertise and also leads to the establishment of European Reference
Networks. In the process of identifying and designating expertise in
rare diseases at national level, hospitals and healthcare workers gen-
erally indicate their expertise. The perception of patients is often not
incorporated. The goal of the project ‘Expertise Mapped’ is to visual-
ise the organisation of care for patients with rare diseases, from pa-
tients’ perspective.
Method
The knowledge maps are based on the EUCERD Quality Criteria, sum-
marized in ten topics (Fig. 1). These maps show on the left side the
perceptions, needs and wishes of patients (gathered by online sur-
veys) and on the right side the competences of the centre (gathered
from visiting the experts by a panel of patients). If there are more
centres of expertise for one rare disease, each centre will get their
own knowledge map.
Results
We produced knowledge maps for 15 different rare diseases, corre-
sponding 27 centres of expertise in the Netherlands. In the next
3 years we will continue producing knowledge maps with the
intention to generate a large and diverse overview of rare diseases
and their centres of expertise. They are published on the website Ex-
pertise Mapped [http://www.expertisemapped.org].
Conclusions
It is important to acknowledge centres of expertise for rare diseases
from patients’ perspective and to visualise the organisation of care.
‘Expertise Mapped’ provides patients, patient organisations and
healthcare workers more insight in the organisation of care, and an
overview of the expertise for rare diseases from patients’ perspective.
Knowledge maps have many advantages:
1. Knowledge maps show where expertise is located and how
healthcare is organised;
2. If there are more centres for the same disease, knowledge
maps give patients the opportunity to choose what fits their
needs;
3. The online survey provides insight into patients’ perspective on
proper care and their actual care needs;
4. Knowledge maps give centres of expertise the opportunity to
show their expertise.
‘Expertise Mapped’ strengthens the position of patients by bundling
and showing the expertise for different rare diseases from the pa-
tients’ perspective. The more knowledge maps are published, the
stronger the patients’ voice.
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Objective
Genetic Alliance UK are undertaking the ‘Hidden Costs’ project, to
test the feasibility of researching the psychosocial and economic
costs of models of health service delivery for rare diseases, from the
perspective of patients, their families and the NHS in the UK.
Method
The feasibility study, overseen by a steering group, focuses on 6 rare
conditions and undiagnosed conditions. The study includes a litera-
ture review, exploratory meetings with patient organisations, semi-
structured interviews (with patients, carers, healthcare professionals
and commissioners) and an assessment of approaches to data
collection.
Results
The literature review has demonstrated that little systematic research
has been conducted in this area, and our understanding of the true
costs and the impact of the way health services are delivered for rare
conditions is limited. Emerging findings confirm that health services
for rare conditions are organised in many different ways, with pa-
tients and families experiencing varying levels or types of care coord-
ination depending on whether they have a diagnosis, which
condition they have, their age, where they live and which service
they choose to access. Qualitative interviews are revealing a range of
different and ‘hidden’ costs that patients and families face as a result
of managing their condition and coordinating their care. Costs in-
clude financial costs, such as those associated with travel to frequent
appointments, and significant psychosocial costs - for patients, par-
ents (of affected children) and wider family members. A huge cost
faced by patients and their parents was time – the time individuals
spent ‘project managing’ their care was described as a significant
burden.
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Managing diagnosed and undiagnosed rare conditions can be stress-
ful and costly, for both families and the NHS. Understanding the full
costs, both economic and psychosocial, of managing rare disease pa-
tients through different models of service coordination will be valu-
able evidence for decision makers and commissioners in the NHS as
they plan service developments and support best practice. A final re-
port detailing the results of the feasibility study will be produced in
2016 to inform future research proposals in this area.
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The Office of Orphan Products Development (OOPD) at the U.S. Food
and Drug Administration (FDA) announced the launch of a new grant
program to fund natural history studies for rare diseases on February
29, 2016.
Successful product development for rare diseases depends on having
a thorough understanding of the disease’s natural history. A natural
history study of a rare disease captures the course a disease takes in
affected individuals from the time immediately prior to its inception,
progressing through a pre-symptomatic phase and different clinical
stages, to a final outcome in the absence of treatment. [1] They can
be useful for defining appropriate outcome measures, biomarkers
and subpopulations.
Information about the natural histories of many rare diseases is often
incomplete or lacking due to the scarcity of patients to study and
lack of resources/funding. While there are nearly 7,000 known rare
diseases, there are only 518 approved orphan drugs and 69 ap-
proved humanitarian use exemption devices (as of January 29, 2016).
Well-conducted natural history studies are needed to expedite the
development, review, and approval of products for the many un-
treated rare diseases. The new natural history grants program ad-
dresses this critical need.
The natural history grants program aims to accelerate the clinical de-
velopment of products for use in rare diseases or conditions where
no current therapy exists or where there is a need for therapy super-
ior to existing therapies. The program supports studies that
characterize the natural history of rare diseases/conditions, including
identifying genotypic and phenotypic subpopulations, and develop-
ing and/or validating clinical outcome measures, biomarkers and/or
companion diagnostics. There are two funding levels for this grant
program. Prospective natural history studies are eligible to be funded
at the maximum of $400,000 in total cost per year for up to five
years. Retrospective natural history studies or survey studies are
eligible to be funded at the maximum of $150,000 in total cost per
year for up to two years. OOPD intends to commit approximately $2
million to the program and award 2-5 grants in Fiscal Year 2017
(October 1, 2016-September 30, 2017). This grant program is open to
all stakeholders in the international rare disease community, includ-
ing patients/patient advocacy groups, clinicians, researchers and in-
dustry partners.Reference
1. Posada de la Paz M, Groft S. Rare diseases epidemiology. Dordrecht:
Springer; 2010
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Background
Those affected by adrenal insufficiency require daily glucocorticoid
hormone replacement therapy. Currently, there is no licensed treat-
ment for patients under 6 years of age in Europe and existing treat-
ment often requires adapting adult doses by crushing tablets. Until
now, little was known about the psychosocial impact of living with
and treating adrenal insufficiency.
Objective
The European Commission funded TAIN project is developing an in-
novative formulation of hydrocortisone for children affected by ad-
renal insufficiency. Genetic Alliance UK is working with parents of
affected children to ensure that their experiences inform the devel-
opment of effective treatments.
Method
Taking a mixed methods approach, Genetic Alliance UK conducted
and analysed 17 semi-structured interviews with parents in the UK.
Subsequently, an online survey was developed, piloted and dissemi-
nated widely to parents of children under the age of 6 in the UK, the
Netherlands and Germany. Detailed analysis is ongoing. The study was
approved by the University of Sheffield’s research ethics committee.
Results
Findings have provided an insight into the wider impact of adrenal
insufficiency, the challenges associated with parenting a child with a
rare condition and the chronic treatment regime. Interviewees re-
ported a lack of awareness of the condition, delays in getting an ac-
curate diagnosis and disparities in care across the UK. Although
parents reported that their child’s condition was relatively well man-
aged, many described a number of challenges associated with the
treatment regime and made suggestions for how it could be im-
proved. They reported disruption to their daily routines, anxiety
about administering the right dose at the right time and difficulties
in delegating responsibility for their child’s care and medication. The
challenges were particularly acute for new parents.
Conclusions
Genetic Alliance UK’s involvement has added value to the TAIN pro-
ject. It has increased understanding of the reality of living with ad-
renal insufficiency from the family perspective. This context is critical
to the development of interventions, which are lacking for many rare
diseases. Dissemination of results to families and stakeholders will
raise awareness and knowledge of the impact of this rare condition.
The research has highlighted unmet needs of families and helped
identify areas for future research and opportunities to influence pol-
icy of benefit to patients. The TAIN project has laid the foundation
for a long-lasting collaboration between patient organisations, indus-
try and academia in the field of adrenal insufficiency and provides a
useful example of the potential benefits of such a partnership.
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Fig. 2 (abstract P20). Innovative patient-centred care pathway
proposed by the INNOVCare project
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People living with a rare disease (RD) and their families have signifi-
cant health and social challenges which affect their dignity, auton-
omy and other fundamental human rights. In order to overcome
these challenges, people living with a RD often need multidisciplin-
ary health, social and local care and support. However, the various
services involved in care provision are commonly managed by differ-
ent authorities and providers, and there is a lack of communication
and coordination between them.
Materials and methods
The objective is to address the gaps in the coordination between
health, social and local services responsible for supporting people liv-
ing with a RD and their families, by developing a holistic persona-
lised care pathway.
The innovative care pathway results from 1) multi-stakeholder work
on the identification of key issues to support the incorporation of RD
into social services, performed within the EUCERD Joint Action for
RDs (2012-2015); and 2) literature review on integrated care provision
in health care settings and beyond.
Results
The innovative care pathway involves linking health services to social
and support services that people living with a RD and their families
use on a daily basis, ensuring the transfer of information and expert-
ise between service providers. The care pathway also centralises the
coordination of care through a resource centre for RD and regional
case managers, in an effort to relieve the burden of care manage-
ment for people living with a RD and their families. This optimised
care model is expected to also result in efficiency gains for national
authorities.
This innovative care pathway is the core of the new EU-funded pro-
ject INNOVCare (Innovative Patient-Centred Approach for Social Care
Provision to Complex Conditions, 2015-2018) and will be implementedin a pilot in Romania. Its socio-economic impact and cost-benefit will
be assessed by social innovation and health economics experts.
Conclusion
The low prevalence and complexity of RD, as well as the significant
unmet needs of RD patients, highlight the need for the implementa-
tion of holistic, integrated and patient-centred care pathways, which
respond to the RD challenges through an interdisciplinary approach.
INNOVCare pilot will be an important step into understanding the
game changing potential of integrated care pathways on the daily
lives and autonomy of people living with a RD and their families.•  We accept pre-submission inquiries 
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